<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935894</url>
  </required_header>
  <id_info>
    <org_study_id>929370</org_study_id>
    <nct_id>NCT02935894</nct_id>
  </id_info>
  <brief_title>Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat</brief_title>
  <official_title>Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>USDA, Western Human Nutrition Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see what the differences are in sweat (amount and small
      molecule content) collected from different sites of the body and by different methods of
      sweat stimulation. Additionally, the investigators want to know whether the amount and small
      molecule content of the sweat is the same in an individual over time, and the same across
      individuals at a given time. Finally, the investigators want to know how consumption of
      over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory
      mediator content of sweat and how that compares to blood. This information will help to
      better understand the composition and behavior of sweat and assess its potential utility as a
      routine clinical tool in skin research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will participate in 4 study day visits that will be scheduled about 1- week apart.
      During the first study visit, the investigators will compare sweat collected following
      pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected
      following physiological stimulation of sweating (using a stationary bicycle). During the
      second study visit, the investigators will collect sweat following stimulation of sweating by
      the drug pilocarpine from the inner part of the forearm (near the wrist) and also the upper
      surface of the thigh (near the knee). During the third study visit, the investigators will
      collect sweat following stimulation of sweating by the drug pilocarpine from the inner part
      of both forearms (near the wrist). During the fourth study visit, the investigators will
      collect a sweat sample following stimulation of sweating by the drug pilocarpine from the
      inner part of the forearm (near the wrist) and a blood sample (about one teaspoon) from the
      other arm. After blood and sweat collection, participants will consume 400 mg (two tablets)
      of ibuprofen. The investigators will then collect blood and sweat from 30 minutes, 2 hours
      and 4 hours after participants consume the ibuprofen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sweat oxidized lipid concentrations in nanomolar</measure>
    <time_frame>measured once from two anatomical sites on four study days</time_frame>
    <description>Using metabolomics approximately 80 oxidized lipids will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sweat endocannabinoid concentrations in nanomolar</measure>
    <time_frame>measured once from two anatomical sites on four study days</time_frame>
    <description>Using metabolomics approximately 30 endocannabinoids will be measured by LC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sweat ceramide concentrations in nanomolar</measure>
    <time_frame>measured once from two anatomical sites on four study days</time_frame>
    <description>Using metabolomics approximately 20 ceramides will be measured by LC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma oxidized lipid concentrations in nanomolar</measure>
    <time_frame>0, 30 minutes, 2 hours and 4 hours</time_frame>
    <description>Using metabolomics, concentrations of approximately 80 oxidized lipids will be measured before and following consumption of ibuprofen using LC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma endocannabinoid concentrations in nanomolar</measure>
    <time_frame>0, 30 minutes, 2 hours and 4 hours</time_frame>
    <description>Using metabolomics, concentrations of approximately 30 endocannabinoids will be measured before and following consumption of ibuprofen using LC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma ceramide concentrations in nanomolar</measure>
    <time_frame>0, 30 minutes, 2 hours and 4 hours</time_frame>
    <description>Using metabolomics, concentrations of approximately 20 ceramides will be measured before and following consumption of ibuprofen using LC-MS/MS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Sweat Ibuprofen Concentration in nanograms per milliliter</measure>
    <time_frame>0, 30 minutes, 2 hours and 4 hours</time_frame>
    <description>Changes in sweat ibuprofen concentrations will be measured by LC-MS/MS following oral administration of 400 mg ibuprofen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasma Ibuprofen Concentration in nanograms per milliliter</measure>
    <time_frame>0, 30 minutes, 2 hours and 4 hours</time_frame>
    <description>Changes in plasma ibuprofen concentrations will be measured by LC-MS/MS following oral administration of 400 mg ibuprofen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat carbohydrates in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using gas chromatography-time of flight mass spectrometry (GC-TOF MS), the relative abundance of carbohydrates in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat sugar phosphates in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of sugar phosphates in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat amino acids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of amino acids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat hydroxyl acids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of hydroxyl acids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat free fatty acids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of free fatty acids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat purines in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of purines in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat pyrimidines in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of pyrimidines in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat aromatics in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using GC-TOF MS, the relative abundance of aromatics in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat sphingomyelin-derived lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using charged surface hybrid-quadrupole time of flight mass spectrometry (CSH-QTOF MS), the relative abundance of sphingomyelin-derived lipids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat cholesteryl ester-derived lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using CSH-QTOF MS, the relative abundance of cholesteryl ester-derived lipids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat oxysterol-derived lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using CSH-QTOF MS, the relative abundance of oxysterol-derived lipids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat phospholipid-derived lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using CSH-QTOF MS, the relative abundance of phospholipid-derived lipids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat galactosyl-lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using CSH-QTOF MS, the relative abundance of galactosyl-lipids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat glucuronyl-lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using CSH-QTOF MS, the relative abundance of glucuronyl-lipids in sweat will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of sweat glycerol-lipids in percent</measure>
    <time_frame>measured once from one anatomical sites on one study day</time_frame>
    <description>Using CSH-QTOF MS, the relative abundance of glycerol-lipids in sweat will be measured.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Stability &amp; Variability of Lipid-derived Molecules in Sweat</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will participate in 4 study day visits in the same order.
compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>400 mg ibuprofen given to inhibit cyclooxygenase metabolism</description>
    <arm_group_label>Single group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiological induction of sweating</intervention_name>
    <description>15 minutes exercise at 60-80% oxygen consumption to induce sweating</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>Exercise</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine</intervention_name>
    <description>Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>Pilogel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-40 y

          -  Male

          -  Body Mass Index 18.5-29.9 kg/m2 (Normal - Overweight)

          -  Weight &gt; 110 pounds

        Exclusion Criteria:

          -  Diagnosed active chronic diseases for which the individual is currently taking daily
             medication, including but not limited to:

               -  Diabetes mellitus

               -  Cardiovascular disease

               -  Cancer

               -  Gastrointestinal disorders

               -  Kidney disease

               -  Liver disease

               -  Bleeding disorders

               -  Asthma

               -  Autoimmune disorders

               -  Hypertension

               -  Osteoporosis

          -  Recent minor surgery (within 4 wk) or major surgery (within 16 wk)

          -  Recent antibiotic therapy (within 4 wk)

          -  Recent hospitalization (within 4 wk)

          -  Use of over-the-counter or prescription medications at the time of the study that
             directly affect endpoints of interest (e.g. hyperlipidemia, glycemic control,
             steroids, statins, anti-inflammatory agents, and weight loss aids)

          -  Adults who are not able to consent

          -  BMI â‰¥ 30 kg/m2

          -  Under current medical supervision

          -  Ibuprofen intolerance or allergy

          -  Those with a bleeding disorder

          -  Current enrollee in a clinical research study.

          -  Individuals with blood clotting or platelet defect disorders

          -  Individuals with orthopedic limitations or cardiovascular risk that preclude
             participation in the physiological stimulation of sweat by light exercise portion of
             the study

          -  Individuals who are trained athletes or that regularly perform physical activity
             defined as &quot;vigorous&quot; by the Centers for Disease Control and Prevention
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W. Newman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA-ARS-Western Human Nutrition Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karan Agrawal, M.Sc.</last_name>
    <phone>530-752-5217</phone>
    <email>kaagrawal@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Western Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen L. Bonnel, Ph.D.</last_name>
      <phone>530-752-4184</phone>
      <email>ellen.bonnel@ars.usda.gov</email>
    </contact>
    <investigator>
      <last_name>John W. Newman, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxygenated lipids</keyword>
  <keyword>metabolic profiling</keyword>
  <keyword>sphingoid bases</keyword>
  <keyword>ceramides</keyword>
  <keyword>endocannabinoids</keyword>
  <keyword>non-invasive sampling</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 23, 2017</submitted>
    <returned>July 20, 2017</returned>
    <submitted>September 29, 2017</submitted>
    <returned>October 27, 2017</returned>
    <submitted>December 11, 2017</submitted>
    <returned>January 8, 2018</returned>
    <submitted>April 30, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

